Speaking yesterday at the Financial Times U.S. Healthcare & Life Sciences Summit, Leonard Schleifer, chief executive officer of Regeneron Pharmaceuticals, sharply criticized the results of a report written by Boston-based Institute for Clinical and Economic Review…
Cancer drugs cost more than $100,000 per year and continue to increase. Medicare has proposed major changes to Medicare Part B in an attempt to slow the explosion in healthcare expenditures.…
Yesterday Sara Edmond, the chief operating officer of the Institute for Clinical and Economic Review and I danced around whether ICER is really patient-centered as she claimed, or rebate-centered as…
An economic formula that counts sick people as fractions could ration health care and penalize cancer patients. But going through cancer has made my life seem more valuable, not less.…
Very few patients have noticed an epic struggle taking place among policy wonks, lobbyists, hedge fund managers and economists in the drug and insurance industries. Some want to describe the…
A lot of the health media was surprised that Amgen decided to criticize ICER before it released its draft decision about the price and access to new medicines for multiple myeloma…
A Boston-based think tank is currently developing policy proposals to measure the “effectiveness and value” of treatment options for a rare blood cancer called multiple myeloma. If you think this…